Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold ...

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold ...

Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

March 27, 2026 10:30 ET  | Source: Celldex Therapeutics, Inc. – Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life –– Data further demonstrates first-in-class and best-in-disease barzolvolimab profile – HAMPTON, N.J., March 27, 2026 (GLOBE NEWSWIRE) — Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 […] The post Celldex Presents Positive Data from Phase 2 Chroni…